Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5230
ISSN (Online): 1875-614X

Research Article

Xylopic Acid Suppresses Adjuvant-induced Arthritis in Sprague Dawley Rats via Reduction in Serum Levels of IL-6 and TNF-alpha

Author(s): Newman Osafo*, Aaron O. Antwi and Sarah Otu-Boakye

Volume 21, Issue 1, 2022

Published on: 19 April, 2022

Page: [46 - 61] Pages: 16

DOI: 10.2174/1871523021666220310094218

Price: $65

Abstract

Background: Xylopic acid (XA) is the principal constituent obtained from the biofractionation of the dried fruits of Xylopia aethiopica. Our initial reports have established the acute anti-inflammatory activity of this kaurene diterpene.

Objective: Currently, we investigate the chronic anti-inflammatory activity of xylopic acid.

Methods: The adjuvant-induced arthritis model in rats was employed in carrying out the study.

Results: It was observed from the study that XA significantly (P < 0.05) suppressed the oedema associated with adjuvant arthritis while preventing associated joint deformation as identified from the radiographs. Histopathological analysis of joints of treated animals revealed signs of bone reformation and re-calcification following XA administration. From the haematological analysis, xylopic acid significantly decreased eosinophil sedimentation rate (ESR) while also decreasing white blood cells (WBC), which were increased after arthritis induction. Serum analysis showed the inhibitory effect of XA on serum expression of IL-6 and TNF-alpha in arthritic rats.

Conclusion: Our study demonstrates the anti-arthritic activity of orally administered XA while pointing to a possible mechanism of its anti-inflammatory action.

Keywords: Adjuvant-induced arthritis, autoimmune disease, inflammation, interleukin-6, tumour necrosis factor-alpha, xylopic acid.

Graphical Abstract
[1]
American college of rheumatology subcommittee on rheumatoid arthritis guidelines. guidelines for the management of rheumatoid arthri-tis: 2002 Update. Arthritis Rheum., 2002, 46(2), 328-346.
[2]
Choy, E.H.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med., 2001, 344(12), 907-916.
[http://dx.doi.org/10.1056/NEJM200103223441207] [PMID: 11259725]
[3]
Mechanisms of bone loss in rheumatoid arthritis. Available from: https://pubmed.ncbi.nlm.nih.gov/17029071/ (Accessed 2021 -09-20).
[4]
Mäkinen, H.; Kautiainen, H.; Hannonen, P.; Möttönen, T.; Leirisalo-Repo, M.; Laasonen, L.; Korpela, M.; Blåfield, H.; Hakola, M.; Sokka, T. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheuma-toid arthritis. J. Rheumatol., 2007, 34(2), 316-321.
[5]
Hoffmann, J.C.; Herklotz, C.; Zeidler, H.; Bayer, B.; Rosenthal, H.; Westermann, J. Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34. Ann. Rheum. Dis., 1997, 56(12), 716-722.
[http://dx.doi.org/10.1136/ard.56.12.716] [PMID: 9496150]
[6]
Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N.M.; Stenson, W.F.; Burr, A.M.; Zhao, W.W.; Kent, J.D.; Lefkowith, J.B.; Verburg, K.M.; Geis, G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal an-ti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284(10), 1247-1255.
[http://dx.doi.org/10.1001/jama.284.10.1247] [PMID: 10979111]
[7]
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. NEJM, Available from: https://www.nejm.org/doi/full/10.1056/NEJM200011233432103 (Accessed 2021 -09 -20).
[8]
Tsakonas, E.; Fitzgerald, A.A.; Fitzcharles, M.A.; Cividino, A.; Thorne, J.C.; M’Seffar, A.; Joseph, L.; Bombardier, C.; Esdaile, J.M. Con-sequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J. Rheumatol., 2000, 27(3), 623-629.
[PMID: 10743799]
[9]
Lard, L.R.; Visser, H.; Speyer, I. vander Horst-Bruinsma, I.E.; Zwinderman, A.H.; Breedveld, F.C.; Hazes, J.M. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med., 2001, 111(6), 446-451.
[http://dx.doi.org/10.1016/S0002-9343(01)00872-5] [PMID: 11690569]
[10]
van Everdingen, A.A.; Jacobs, J.W.G.; Siewertsz Van Reesema, D.R.; Bijlsma, J.W.J. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med., 2002, 136(1), 1-12.
[http://dx.doi.org/10.7326/0003-4819-136-1-200201010-00006] [PMID: 11777359]
[11]
Landewé, R.B.M.; Boers, M.; Verhoeven, A.C.; Westhovens, R.; van de Laar, M.A.F.J.; Markusse, H.M.; van Denderen, J.C.; Westedt, M.L.; Peeters, A.J.; Dijkmans, B.A.C.; Jacobs, P.; Boonen, A.; van der Heijde, D.M.F.M.; van der Linden, S. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum., 2002, 46(2), 347-356.
[http://dx.doi.org/10.1002/art.10083] [PMID: 11840436]
[12]
Lipsky, P.E.; van der Heijde, D.M.; St Clair, E.W.; Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Weisman, M.; Emery, P.; Feld-mann, M.; Harriman, G.R.; Maini, R.N. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med., 2000, 343(22), 1594-1602.
[http://dx.doi.org/10.1056/NEJM200011303432202] [PMID: 11096166]
[13]
Osafo, N.; Biney, R. P.; Obiri, D. Aqueous ethanol fruit extract of xylopia aethiopica and xylopic acid exhibit anti-inflammatory activity through inhibition of the arachidonic acid pathway. 2016.
[http://dx.doi.org/10.20510/ukjpb/4/i6/134665]
[14]
Ekong, D.; Ogan, A. Chemistry of the constituents of xylopia aethiopica. The Structure of Xylopic Acid, a New Diterpene Acid J. Chem. Soc. C, 1968, 21, 311-312.
[http://dx.doi.org/10.1039/j39680000311]
[15]
Seasonal variation of kaurenoic acid, a hypoglycemic diterpene present in Wedelia paludosa (Acmela brasiliensis) (Asteraceae). Available from: https://pubmed.ncbi.nlm.nih.gov/15241932/(Accessed 2021 -09-20).
[16]
Osafo, N.; Obiri, D.D.; Antwi, A.O.; Yeboah, O.K. The acute anti-inflammatory action of xylopic acid isolated from Xylopia aethiopica. J. Basic Clin. Physiol. Pharmacol., 2018, 29(6), 659-669.
[http://dx.doi.org/10.1515/jbcpp-2018-0019] [PMID: 30052517]
[17]
Alolga, R.N.; Opoku-Damoah, Y.; Alagpulinsa, D.A.; Huang, F-Q.; Ma, G.; Chavez Leon, M.A.S.C.; Kudzai, C.; Yin, X.; Ding, Y. Metabo-lomic and transcriptomic analyses of the anti-rheumatoid arthritis potential of xylopic acid in a bioinspired lipoprotein nanoformulation. Biomaterials, 2021, 268, 120482.
[http://dx.doi.org/10.1016/j.biomaterials.2020.120482] [PMID: 33307367]
[18]
Osafo, N.; Obiri, D.D.; Danquah, K.O.; Essel, L.B.; Antwi, A.O. Potential effects of xylopic acid on acetic acid-induced ulcerative colitis in rats. Turk. J. Gastroenterol., 2019, 30(8), 732-744.
[http://dx.doi.org/10.5152/tjg.2019.18389] [PMID: 31418418]
[19]
Pearson, C.M. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc. Soc. Exp. Biol. Med., 1956, 91(1), 95-101.
[20]
Binder, W.; Walker, J.S. Effect of the peripherally selective kappa-opioid agonist, asimadoline, on adjuvant arthritis. Br. J. Pharmacol., 1998, 124(4), 647-654.
[http://dx.doi.org/10.1038/sj.bjp.0701874] [PMID: 9690855]
[21]
Obiri, D.D.; Osafo, N.; Ayande, P.G.; Antwi, A.O. Xylopia aethiopica (Annonaceae) fruit extract suppresses Freund’s adjuvant-induced arthritis in Sprague-Dawley rats. J. Ethnopharmacol., 2014, 152(3), 522-531.
[http://dx.doi.org/10.1016/j.jep.2014.01.035] [PMID: 24509151]
[22]
Cai, X.; Zhou, H.; Wong, Y.F.; Xie, Y.; Liu, Z.Q.; Jiang, Z.H.; Bian, Z.X.; Xu, H.X.; Liu, L. Suppressive effects of QFGJS, a preparation from an anti-arthritic herbal formula, on rat experimental adjuvant-induced arthritis. Biochem. Biophys. Res. Commun., 2005, 337(2), 586-594.
[http://dx.doi.org/10.1016/j.bbrc.2005.09.083] [PMID: 16199007]
[23]
Pohlers, D.; Beyer, A.; Koczan, D.; Wilhelm, T.; Thiesen, H-J.; Kinne, R.W. Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res. Ther., 2007, 9(3), R59.
[http://dx.doi.org/10.1186/ar2217] [PMID: 17594488]
[24]
Arikan, S.; Akalin, N. Comparison of the erythrocyte sedimentation rate measured by the Micro Test 1 sedimentation analyzer and the conventional Westergren method. Ann. Saudi Med., 2007, 27(5), 362-365.
[http://dx.doi.org/10.5144/0256-4947.2007.362] [PMID: 17921682]
[25]
Kitamura, T.; Murase, T.; Hashimoto, J.; Tomita, T.; Arimitsu, S.; Yoshikawa, H.; Sugamoto, K. Radiographic study on the pattern of wrist joint destruction in rheumatoid arthritis. Clin. Rheumatol., 2011, 30(3), 353-359.
[http://dx.doi.org/10.1007/s10067-010-1575-3] [PMID: 20857155]
[26]
Bohndorf, K.; Schalm, J. Diagnostic radiography in rheumatoid arthritis: benefits and limitations. Baillieres Clin. Rheumatol., 1996, 10(3), 399-407.
[http://dx.doi.org/10.1016/S0950-3579(96)80038-0] [PMID: 8876948]
[27]
Rheumatoid Arthritis. Rheumatoid Arthritis: What is RA? Symptoms, Diagnosis, Treatment. Available from: https://www.webmd.com/rheumatoid-arthritis/rheumatoid-arthritis-basics (Accessed 2021 -09 -20).
[28]
Rheumatoid Arthritis (RA) - Musculoskeletal and Connective Tissue Disorders. Available from: https://www.msdmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/joint-disorders/rheumatoid-arthritis-ra (Accessed 2021 -09 -20).
[29]
Soren, A. The diagnostic significance of certain histopathologic changes for rheumatoid arthritis. Z. Rheumatol., 1980, 39(3-4), 74-78.
[PMID: 7424201]
[30]
Feldmann, M.; Maini, S.R.N. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev., 2008, 223, 7-19.
[http://dx.doi.org/10.1111/j.1600-065X.2008.00626.x] [PMID: 18613827]
[31]
Cawthorn, W.P.; Sethi, J.K. TNF-alpha and adipocyte biology. FEBS Lett., 2008, 582(1), 117-131.
[http://dx.doi.org/10.1016/j.febslet.2007.11.051] [PMID: 18037376]
[32]
Ramprasath, V.R.; Shanthi, P.; Sachdanandam, P. Immunomodulatory and anti-inflammatory effects of Semecarpus anacardium LINN. Nut milk extract in experimental inflammatory conditions. Biol. Pharm. Bull., 2006, 29(4), 693-700.
[http://dx.doi.org/10.1248/bpb.29.693] [PMID: 16595901]
[33]
Obiri, D.D.; Osafo, N.; Oppong-Sarfo, J.; Prah, J.K. Margaritaria discoidea (Euphorbiaceae) stem bark extract attenuates allergy and Freund’s adjuvant-induced arthritis in rodents. Pharmacognosy Res., 2014, 6(2), 163-171.
[http://dx.doi.org/10.4103/0974-8490.129039] [PMID: 24761122]
[34]
Obiri, D.D.; Osafo, N.; Dei-Anane, S.; Adjei, R.K.; Ababio, E.O. Anti-allergic, anti-inflammatory and analgesic actions of stem bark extract of Lannea welwitschii (anarcadiaceae) in mice. Int. J. Pharm. Pharm. Sci., 2013, 5, 217-222.
[35]
Turull, A.; Queralt, J. Selective cyclooxygenase-2 (COX-2) inhibitors reduce anti-Mycobacterium antibodies in adjuvant arthritic rats. Immunopharmacology, 2000, 46(1), 71-77.
[http://dx.doi.org/10.1016/S0162-3109(99)00159-9] [PMID: 10665781]
[36]
Harrison’s Principles of Internal Medicine, Available from: https://accessmedicine.mhmedical.com/book.aspx?bookID=2129 (Accessed 2021 -09 -20).
[37]
Atzeni, F.; Sarzi-Puttini, P. [Early rheumatoid arthritis]. Reumatismo, 2007, 59(2), 100-117. [Early rheumatoid arthritis].
[http://dx.doi.org/10.4081/reumatismo.2007.100] [PMID: 17603690]
[38]
Castrillo, A.; de Las Heras, B.; Hortelano, S.; Rodriguez, B.; Villar, A.; Bosca, L. Inhibition of the nuclear factor kappa B (NF-kappa B) pathway by tetracyclic kaurene diterpenes in macrophages. Specific effects on NF-kappa B-inducing kinase activity and on the coordinate activation of ERK and p38 MAPK. J. Biol. Chem., 2001, 276(19), 15854-15860.
[http://dx.doi.org/10.1074/jbc.M100010200] [PMID: 11278990]
[39]
Leung, C-H.; Grill, S.P.; Lam, W.; Han, Q-B.; Sun, H-D.; Cheng, Y-C. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol. Pharmacol., 2005, 68(2), 286-297.
[http://dx.doi.org/10.1124/mol.105.012765] [PMID: 15872117]
[40]
Sosa-Sequera, M.C.; Suárez, O.; Daló, N.L. Kaurenic acid: An in vivo experimental study of its anti-inflammatory and antipyretic effects. Indian J. Pharmacol., 2010, 42(5), 293-296.
[http://dx.doi.org/10.4103/0253-7613.70205] [PMID: 21206621]
[41]
Hanauer, S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis., 2006, 12(Suppl. 1), S3-S9.
[http://dx.doi.org/10.1097/01.MIB.0000195385.19268.68] [PMID: 16378007]
[42]
Podolsky, D.K. Inflammatory bowel disease. N. Engl. J. Med., 2002, 347(6), 417-429.
[http://dx.doi.org/10.1056/NEJMra020831] [PMID: 12167685]
[43]
The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Available from:https://pubmed.ncbi.nlm.nih.gov/17590166/ (Accessed 2021 -09 -20).
[44]
Zwerina, J.; Hayer, S.; Redlich, K.; Bobacz, K.; Kollias, G.; Smolen, J.S.; Schett, G. Activation of p38 MAPK is a key step in tumor necro-sis factor-mediated inflammatory bone destruction. Arthritis Rheum., 2006, 54(2), 463-472.
[http://dx.doi.org/10.1002/art.21626] [PMID: 16447221]
[45]
Zhang, X.; Sun, J.; Xin, W.; Li, Y.; Ni, L.; Ma, X.; Zhang, D.; Zhang, D.; Zhang, T.; Du, G. Anti-inflammation effect of methyl salicylate 2-O-β-D-lactoside on adjuvant induced-arthritis rats and lipopolysaccharide (LPS)-treated murine macrophages RAW264.7 cells. Int. Immunopharmacol., 2015, 25(1), 88-95.
[http://dx.doi.org/10.1016/j.intimp.2015.01.024] [PMID: 25637446]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy